3920 Stock Overview
A preclinical stage biotechnology company, focuses on developing therapeutics for patients living with inflammatory bowel disease (IBD). More details
| Snowflake Score | |
|---|---|
| Valuation | 1/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
Spyre Therapeutics, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$25.40 |
| 52 Week High | US$40.90 |
| 52 Week Low | US$20.90 |
| Beta | 2.91 |
| 11 Month Change | -16.99% |
| 3 Month Change | 6.95% |
| 1 Year Change | n/a |
| 33 Year Change | n/a |
| 5 Year Change | n/a |
| Change since IPO | -26.38% |
Recent News & Updates
Recent updates
Shareholder Returns
| 3920 | DE Biotechs | DE Market | |
|---|---|---|---|
| 7D | -6.8% | -0.7% | 0.2% |
| 1Y | n/a | -17.2% | 8.5% |
Return vs Industry: Insufficient data to determine how 3920 performed against the German Biotechs industry.
Return vs Market: Insufficient data to determine how 3920 performed against the German Market.
Price Volatility
| 3920 volatility | |
|---|---|
| 3920 Average Weekly Movement | 8.9% |
| Biotechs Industry Average Movement | 6.5% |
| Market Average Movement | 4.8% |
| 10% most volatile stocks in DE Market | 10.9% |
| 10% least volatile stocks in DE Market | 2.3% |
Stable Share Price: 3920's share price has been volatile over the past 3 months compared to the German market.
Volatility Over Time: 3920's weekly volatility (9%) has been stable over the past year, but is still higher than 75% of German stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2013 | 60 | Cameron Turtle | www.spyre.com |
Spyre Therapeutics, Inc., a preclinical stage biotechnology company, focuses on developing therapeutics for patients living with inflammatory bowel disease (IBD). It develops SPY001, a human monoclonal immunoglobulin G1 antibody designed to bind selectively to the a4ß7 integrin being developed for the treatment of IBD (ulcerative colitis and Crohn’s disease). The company is also developing SPY002, a human monoclonal antibody (mAb)candidates designed to bind to tumor necrosis factor-like ligand 1A; and SPY120, a combination of SPY001 (anti-a4ß7) and SPY002 (anti-TL1A) antibodies, which are in preclinical studies.
Spyre Therapeutics, Inc. Fundamentals Summary
| 3920 fundamental statistics | |
|---|---|
| Market cap | €1.56b |
| Earnings (TTM) | -€206.37m |
| Revenue (TTM) | n/a |
0.0x
P/S Ratio-7.6x
P/E RatioIs 3920 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 3920 income statement (TTM) | |
|---|---|
| Revenue | US$0 |
| Cost of Revenue | US$84.05m |
| Gross Profit | -US$84.04m |
| Other Expenses | US$130.86m |
| Earnings | -US$214.90m |
Last Reported Earnings
Sep 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -3.66 |
| Gross Margin | 0.00% |
| Net Profit Margin | 0.00% |
| Debt/Equity Ratio | 0% |
How did 3920 perform over the long term?
See historical performance and comparison